|
KMID : 1001020220200010012
|
|
Journal of Urologic Oncology
2022 Volume.20 No. 1 p.12 ~ p.24
|
|
|
New Drugs for Bacillus Calmette Guerin-Unresponsive Nonmuscle Invasive Bladder Cancer
|
|
Jeong Jae-Woon
Ha Jae-Baek
Chang In-Ho
|
|
|
Abstract
|
|
|
|
For intermediate- and high-risk nonmuscle invasive bladder cancer (NMIBC), intravesical Bacil-lus Calmette-Guerin (BCG) therapy is the standard adjuvant treatment following transurethral resection of bladder tumor. Although intravesical BCG therapy improves disease progression and bladder preservation in most patients, there are still a considerable number of BCG-unresponsive cases, for whom radical cystectomy (RC) is the recommended salvage treatment option. However, RC is associated with high morbidity and mortality rates, and alternative treat-ment options are needed. New approaches, such as intravesical chemotherapy, device-assisted treatments, immune checkpoint inhibitors, viral gene therapy, antibody-drug conjugates, fibroblast growth factor receptor inhibitors, and other novel agents are being investigated. This review aims to provide an overview of the recent trials for BCG-unresponsive NMIBC.
|
|
|
KEYWORD
|
|
|
Antibody-drug conjugate, Bacillus Calmette-Guerin, Immune checkpoint inhibi-tors, Oncolytic virotherapy, Urinary bladder neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|